Edgar Tracker

ADCT ADC Therapeutics SA

NYSE · CIK 1771910 · Pharmaceutical Preparations

SEC company page

Public articles

ADCT · Parts · 4c5ebd435623567a

AI summary

ADC Therapeutics SA ADCT — Proposed Swiss to Delaware redomiciliation; no cash consideration disclosed Filing Summary ADC Therapeutics SA’s November 3, 2026 S 4 proposes continuin…

Recent filings

–

Form Filed Title Accession
S-42026-11-03FORM S-4 Article0000950103-26-016858
SCHEDULE 13G2026-10-29—0001193125-26-438199
8-K2026-10-131.01 Entry into a Material Definitive Agreement · 2.02 Results of Operations and Financial Condition · 3.02 Unregistered Sales of Equity Securities · 9.01 Financial Statements and Exhibits0000950103-26-015465
SCHEDULE 13G2026-08-14—0001104659-26-097255
S-82026-08-13FORM S-80000950103-26-012337
10-Q2026-08-1310-Q0001628280-26-056711
8-K2026-08-132.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits0000950103-26-012287
SCHEDULE 13G2026-07-27—0002012383-26-002147
8-K2026-07-025.02 Departure/Election of Directors or Principal Officers0000950103-26-010195
8-K2026-06-247.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits0000950103-26-009416
8-K2026-06-037.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits0000950103-26-008465
8-K2026-06-025.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits0000950103-26-008321
10-Q2026-05-0410-Q0001628280-26-029819
8-K2026-05-042.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits0001628280-26-029524
SCHEDULE 13G/A2026-04-24—0001104659-26-048804
DEFA14A2026-04-20FORM DEFA14A0000950103-26-005918
DEF 14A2026-04-20DEF 14A0001140361-26-015491
424B32026-04-15FORM 424B30000950103-26-005754
PRE 14A2026-04-10PRE 14A0001140361-26-014246
SCHEDULE 13G/A2026-04-06—0001104659-26-040084